Science library
Evidence library
Primary sources for field context, plus a clear wall between wider CBD research and evidence generated with NWPT’s own formulation.
How to read this page: “Field” entries describe the broader literature. They are not claims about NWPT-SM32300. “Other product” rows concern formulations and populations that are not this programme. Product-specific rows stay free of efficacy claims until signed study reports exist.
Field — clinical high risk
| Source | What it supports | Limitations | Label |
|---|---|---|---|
|
Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-229.
doi:10.1001/archgenpsychiatry.2011.1472 · PubMed 22393215 |
Quantifies elevated transition risk in clinical high-risk samples relative to the general population; underpins why early-intervention research is scientifically motivated. | Pooled rates vary by era, enrichment and setting; meta-analytic averages are not individual prognoses and are not NWPT programme results. | Field |
|
Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11-12):964-971.
doi:10.1080/j.1440-1614.2005.01714.x · PubMed 16343296 |
Describes CAARMS and ultra-high-risk criteria used widely to operationalise clinical high-risk assessment in research. | Instrument and criteria define research eligibility constructs — not a schizophrenia diagnosis and not evidence for any specific drug. | Field |
|
Cannon TD, Yu C, Addington J, et al. An individualized risk calculator for research in prodromal psychosis. Am J Psychiatry. 2016;173(10):980-988.
doi:10.1176/appi.ajp.2016.15070890 · PubMed 27363508 |
Shows how enrichment and individual risk profiles change expected event rates — relevant to trial design and sample-size thinking. | Research prediction tool; external validity depends on population and predictors. Not a claim about NWPT-SM32300. | Field |
|
Salazar de Pablo G, Radua J, Pereira J, et al. Probability of Transition to Psychosis in Individuals at Clinical High Risk: An Updated Meta-analysis. JAMA Psychiatry. 2021;78(9):970-978.
doi:10.1001/jamapsychiatry.2021.0830 · PubMed 34259821 |
Updated synthesis of cumulative transition probabilities over follow-up; reinforces that risk is elevated yet heterogeneous across studies. | High between-study heterogeneity; cumulative risks are not destiny for any one person and do not establish treatment effects for this programme. | Field |
Other product — cannabidiol (not NWPT-SM32300)
CBD has been studied in psychosis and related conditions using other formulations. Those data inform hypotheses; they do not equal results for NWPT-SM32300, and they are not CHR-P prevention trials for this candidate.
| Source | What it supports | Limitations | Label |
|---|---|---|---|
|
McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry. 2018;175(3):225-231.
doi:10.1176/appi.ajp.2017.17030325 · PubMed 29241357 |
Adjunctive CBD in established schizophrenia (other product / population context) — hypothesis-generating for cannabinoid research in psychosis more broadly. | Not NWPT-SM32300. Not a CHR-P prevention study. Different population, product and clinical question. | Other product |
| Epidiolex / Epidyolex regulatory labelling (epilepsy indications) | Documents approved uses for a different CBD product in epilepsy — useful context for how another formulation has been regulated. | Approved epilepsy indications are not CHR-P psychosis prevention and are not NWPT-SM32300 labelling. | Other product |
NWPT-SM32300 — programme-specific
| Item | Status | Visitor note |
|---|---|---|
| Candidate description | Described in company materials as NWPT-SM32300 (300 mg CBD micellar-emulsion softgel) | Investigational product description only — not an approved medicine for CHR-P. |
| Comparative bioavailability vs Epidyolex | Formal clinical study report not yet published here | No numerical PK or safety figures on this site until a signed clinical study report is on file. |
| CHR-P efficacy / prevention of psychosis | Not established | Prevention of psychosis is the mission and research question — not a demonstrated result for this candidate. |
| Historical multi-site prevention plans (~328 participants) | Planning precedent only; synopsis in development | Earlier large-design figures are useful history — they are not a locked protocol for this programme. |